About GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) is a protein
from Homo sapiens identified by UniProt accession
P52961, 327 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 |
|---|
| UniProt accession | P52961 |
|---|
| Gene | ART1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (26)
Diseases linked to this target (Open Targets).
- cutaneous melanoma · score 0.22
- lung adenocarcinoma · score 0.22
- visual perception measurement · score 0.20
- glioblastoma multiforme · score 0.20
- head and neck squamous cell carcinoma · score 0.15
- gastric adenocarcinoma · score 0.12
- breast adenocarcinoma · score 0.10
- DNA methylation · score 0.10
- neoplasm · score 0.03
- blood protein measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P52961-F1 | alphafold | PREDICTED | 84.66 | — |
Amino-acid sequence (327 residues)
MQMPAMMSLL LVSVGLMEAL QAQSHPITRR DLFSQEIQLD MALASFDDQY AGCAAAMTAA LPDLNHTEFQ ANQVYADSWT LASSQWQERQ ARWPEWSLSP TRPSPPPLGF RDEHGVALLA YTANSPLHKE FNAAVREAGR SRAHYLHHFS FKTLHFLLTE ALQLLGSGQR PPRCHQVFRG VHGLRFRPAG PRATVRLGGF ASASLKHVAA QQFGEDTFFG IWTCLGAPIK GYSFFPGEEE VLIPPFETFQ VINASRLAQG PARIYLRALG KHSTYNCEYI KDKKCKSGPC HLDNSAMGQS PLSAVWSLLL LLWFLVVRAF PDGPGLL
Explore GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets